Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of hepatitis infections
3.2.1.2 Advancements in drug development
3.2.1.3 Rising demand for combination therapies
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of medications
3.2.2.2 Side effects and adverse reactions
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Hepatitis A
5.3 Hepatitis B
5.4 Hepatitis C
5.5 Other hepatitis types
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Anti-viral drugs
6.2.1 Nucleoside/nucleotide analogues
6.2.2 Polymerase inhibitors
6.2.3 Protease inhibitors
6.2.4 Other anti-viral drugs
6.3 Immune modulators (interferons)
6.4 Combination therapies
6.5 Liver transplant
6.6 Other treatment types
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By End-user, 2021–2032 ($ Mn)
8.1 Key trends
8.2 Healthcare providers
8.2.1 Hospitals
8.2.2 Specialty clinics
8.3 Patients
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Service Provider
10.1.1 Barnes-Jewish Hospital
10.1.2 Bumrungrad International Hospital
10.1.3 Cedars-Sinai
10.1.4 Cleveland Clinic
10.1.5 Mayo Clinic
10.2 Medication Manufacturers
10.2.1 AbbVie Inc.
10.2.2 Biocon, Inc.
10.2.3 Bristol-Myers Squibb Company
10.2.4 Dynavax Technologies
10.2.5 F. Hoffmann-La Roche Ltd.
10.2.6 Gilead Sciences, Inc.
10.2.7 GlaxoSmithKline plc
10.2.8 Lupin Limited
10.2.9 Merck & Co., Inc.
10.2.10 Novartis AG
